Cargando…

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV

The integrase inhibitor dolutegravir was included in initial antiretroviral therapy in Brazil in January 2017. Studies have demonstrated that the efficacy and safety of antiretrovirals have improved with the introduction of new classes of antiretrovirals, such as integrase inhibitors. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Correa, Analú, Monteiro, Polyana, Calixto, Fernanda, Batista, Joanna d’Arc Lyra, de Alencar Ximenes, Ricardo Arraes, Montarroyos, Ulisses Ramos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458288/ https://www.ncbi.nlm.nih.gov/pubmed/32866163 http://dx.doi.org/10.1371/journal.pone.0238052

Ejemplares similares

Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS
por: Azevedo, Larissa Negromonte, et al.
Publicado: (2019)

Effectiveness of four antiretroviral regimens for treating people living with HIV
por: Cavalcanti, Aracele Tenório de Almeida e, et al.
Publicado: (2020)

Smoking increases the risk of relapse after successful tuberculosis treatment
por: d’Arc Lyra Batista, Joanna, et al.
Publicado: (2008)

Incidence and Risk Factors for Tuberculosis in People Living with HIV: Cohort from HIV Referral Health Centers in Recife, Brazil
por: Batista, Joanna d’Arc Lyra, et al.
Publicado: (2013)

Validating a Scoring System for the Diagnosis of Smear-Negative Pulmonary Tuberculosis in HIV-Infected Adults
por: Coimbra, Isabella, et al.
Publicado: (2014)

ASSOCIATION BETWEEN SMOKING, CRACK COCAINE ABUSE AND THE DISCONTINUATION OF COMBINATION ANTIRETROVIRAL THERAPY IN RECIFE, PERNAMBUCO, BRAZIL
por: Batista, Joanna d'Arc Lyra, et al.
Publicado: (2014)

Use of the Coding Causes of Death in HIV in the classification of deaths in Northeastern Brazil
por: Alves, Diana Neves, et al.
Publicado: (2017)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

2488. Virologic Failure in ART Naïve Patients Initiating on a Dolutegravir or Elvitegravir-Based Regimen
por: Wohlfeiler, Michael, et al.
Publicado: (2019)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen: a prospective cohort study
por: Keene, Claire M, et al.
Publicado: (2021)

Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
por: Llibre, Josep M, et al.
Publicado: (2022)

An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS
por: Moura, Líbia CRV, et al.
Publicado: (2011)

549. Weight and BMI Changes in HIV-Infected Virologically Suppressed Adults after Switching to an Elvitegravir- or Dolutegravir-Containing Regimen
por: Gibson, Amanda, et al.
Publicado: (2018)

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study
por: Phillips, Andrew N, et al.
Publicado: (2018)

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania
por: Mutagonda, Ritah F., et al.
Publicado: (2022)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

Virological Suppression and Its Associated Factors of Dolutegravir Based Regimen in a Resource-Limited Setting: An Observational Retrospective Study in Ethiopia
por: Mehari, Eden Abetu, et al.
Publicado: (2021)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Risk factors for subclinical atherosclerosis in HIV-infected patients under and over 40 years: a case–control study
por: Albuquerque, Valéria Maria Gonçalves, et al.
Publicado: (2013)

Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens
por: Rhee, Soo-Yon, et al.
Publicado: (2020)

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy
por: Hailu, Workagegnehu, et al.
Publicado: (2021)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

Protocol for active safety monitoring of a cohort of patients using a dolutegravir-based antiretroviral regimen in Mozambique
por: Mussá, Merana, et al.
Publicado: (2021)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2019)

Factors Related to Changes in CD4+ T-Cell Counts over Time in Patients Living with HIV/AIDS: A Multilevel Analysis
por: Montarroyos, Ulisses Ramos, et al.
Publicado: (2014)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis
por: Cruciani, Mario, et al.
Publicado: (2019)

Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144
por: Wang, Ruolan, et al.
Publicado: (2023)

Severe Thrombocytopenia During Dolutegravir-containing Antiretroviral Therapy
por: Nakaharai, Kazuhiko, et al.
Publicado: (2017)

Virological Non-Suppression among Newly Diagnosed HIV-Positive Individuals on Dolutegravir-Based Antiretroviral Treatment in Eastern Ethiopia: Follow-Up Study
por: Gemechu, Abdella, et al.
Publicado: (2023)

The frequency and clinical presentation of Zika virus coinfections: a systematic review
por: Lobkowicz, Ludmila, et al.
Publicado: (2020)

Virological outcome and frequency of low-level viremia in patients receiving generic dolutegravir-containing regimen at a large tertiary care clinic in Western India
por: Patel, Atul K., et al.
Publicado: (2021)

Comparison of Antiretroviral Regimens: Adverse Effects and Tolerability Failure that Cause Regimen Switching
por: Kim, Min Jung, et al.
Publicado: (2015)

Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study
por: Ayal, Melese Alemnew, et al.
Publicado: (2023)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1dbiiahrfsbfpkt41u8fglpstp